Insider buying last 90 days
No open-market insider purchases were filed for RGEN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Repligen's record third quarter headlines the week, with revenue of $209 million reflecting 12.5% organic growth and 170 basis points of adjusted operating margin expansion year-over-year, alongside the closed BioLife acquisition expected to add $24 million in fourth-quarter revenue. Investors also weighed a Q3 net loss of $38.43 million, driven by $41.24 million in intangible asset impairment charges and new convertible senior notes. RBC Capital Markets reiterated an Outperform rating, citing confidence in filtration business growth returning to historical rates next year, while Stifel maintained a Buy rating with a $207 price target, pointing to upside from the Biolife deal and margin synergies. Repligen's CEO is also set to join an analyst discussion in London on 18 November.
The stock closed at $178.94, up 3.1%, sitting above both its 50-day average of $177.40 and 200-day average of $145.08, with the 50-day above the 200-day. The GekkoIndex reads 56.4, placing it in the Neutral zone, down 3.8 over five days. Price sits 8% above Gekko Fair Value of $165.70.
Over the next 20 trading days, the next earnings date falls on 23 February 2027, outside this window. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows, though one billionaire holder and two trailblazer holders are noted. Seasonality over five years shows an average 20-day return of 1.3%, rising in 2 of those years. Consensus among 9 analysts stands at 8 buy, 1 hold, with a target of $203.45.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Repligen scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive2 mixed0 headwinds
Averages disagree
Close $167.79 sits between the 50-day ($177.15) and 200-day ($145.27) averages, or the averages disagree.
See the chart61, Accumulation
Reading 61 is in the Accumulation zone.
See the GekkoIndex1.2% above
Price is within 5% of Gekko Fair Value (1.2% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 100 days
Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.
See earnings+1.6% on average
From this point in the calendar, the next 20 trading days averaged +1.6% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Repligen closed at $167.79 on Nov 13, 2026, +6.2% over the past year, inside a 52-week range of $100.99 to $198.87.
Use the left and right arrow keys to read daily values.
Put RGEN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Repligen builds tools and equipment that support the manufacture of biologic drugs, covering several steps of that process. Among its best known items are Protein A ligands used inside affinity chromatography resins, along with its OPUS pre-packed columns for purifying biologics and smaller OPUS formats used for screening, viral clearance testing and scaled-down purification work. The company also makes ELISA kits, CaptivA-branded resins, and a wide range of filtration gear including XCell Alternating Tangential Flow units, TangenX flat sheet cassettes, KrosFlo tangential flow and depth filtration systems, Spectra/Por dialysis products, SpectraFlo dialysis units, ProConnex single-use hollow fibers, and spectroscopy instruments sold as SoloVPE, FlowVPE and FlowVPX.
Its customer base spans life sciences groups, biopharma and diagnostics firms, academic and industry researchers, and contract manufacturers, with sales reaching organizations in North America, Europe, Asia Pacific and elsewhere. Repligen also teams up with outside firms, among them Navigo Proteins GmbH, to jointly develop affinity ligand technology.
The company traces back to 1981 and runs its headquarters out of Waltham, Massachusetts. Its stock trades on the NASDAQ under the ticker RGEN.
Repligen’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 61, in the Accumulation zone, up 2 points over five sessions.
Up 2 points over five sessions, from the Neutral zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 48 | −0.6% | −3.0% | ||
| Accumulation (current zone) | 222 | +1.3% | +2.6% | ||
| Neutral | 396 | −0.3% | 0.0% | ||
| Distribution | 35 | +0.1% | −2.6% | ||
| Selling | 1 | Too few readings yet | |||
Average RGEN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Repligen trades 1.2% above Gekko Fair Value of $165.83, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Repligen shares are worth, recalculated every trading day.
$165.83
Gekko Fair Value, Nov 14, 2026
1.2% above fair value · About fair value
At the end of Aug 2026 the price was 3.9% above the estimate.
No open-market insider purchases were filed for Repligen, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for RGEN in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in RGEN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Repligen has been buying back its own shares.
From company filings.
2of the funds Gekko tracks hold RGEN.
Repligen reports on Feb 23, 2027, before the open (100 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 23, 2027
Expected before the open, 100 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 27, 2026 | $0.53 est $0.46 | $209.3M est $206.7M | +2.5% |
| Jul 28, 2026 | $0.54 est $0.45 | $204.1M est $201.6M | +7.8% |
| May 5, 2026 | $0.48 est $0.39 | $194.3M est $192.1M | +6.4% |
| Feb 24, 2026 | $0.49 est $0.44 | $197.9M est $192.9M | −2.4% |
| Oct 28, 2025 | $0.46 est $0.42 | $188.8M est $192.2M | −7.8% |
| Jul 29, 2025 | $0.37 est $0.40 | $182.4M est $181.8M | +2.7% |
| Apr 29, 2025 | $0.39 est $0.35 | $169.2M est $173.6M | −3.9% |
| Feb 20, 2025 | $0.44 est $0.42 | $167.5M est $164.1M | +5.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Repligen is $203.21, +21.1% from the last close, from 9 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 9 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 11 | Stifel Nicolaus | $207 | +23.4% |
| Nov 2 | Stifel Nicolaus | $207 | +23.4% |
| Nov 1 | RBC Capital | $200 | +19.2% |
| Oct 29 | J.P. Morgan | $205 | +22.2% |
| Oct 28 | Canaccord Genuity | $180 | +7.3% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Repligen averaged +1.6% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.5% | 3 of 5 |
| Next 10 trading days | +1.1% | 3 of 5 |
| Next 15 trading days | −3.0% | 2 of 5 |
| Next 20 trading days | +1.6% | 3 of 5 |
| Next 30 trading days | +1.4% | 2 of 5 |
For scale, RGEN’s typical 20-trading-day move in either direction is about 7.5%.
Repligen’s market cap is $10.73B and revenue of $805.6M over the last twelve months.
2 headlines about Repligen from the past week, newest first, each linking to the publisher.
Repligen’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Repligen’s market cap is $10.73B at the Nov 13, 2026 close of $167.79, with 63.92M shares outstanding.
The consensus analyst 12-month price target for Repligen is $203.21, +21.1% from the last close. Of the 9 firms that rated the stock in the last 90 days, 8 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Repligen is about fair value: the Nov 13, 2026 close of $167.79 is 1.2% above Gekko Fair Value of $165.83. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Repligen is expected to report on Feb 23, 2027, before the market opens (100 days away). Analysts expect earnings of $0.54 per share on revenue of $241.0M. Repligen beat the earnings estimate in 7 of its last 8 reports, moving 4.9% on average across the report.
Repligen’s 52-week high is $198.87 and its 52-week low is $100.99; it closed at $167.79 on Nov 13, 2026, +6.2% over the past year. Over the last five years the shares peaked at $300.23 on Nov 26, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, earnings risk and seasonality), 2 as mixed (trend and fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.